AURA NASDAQ
Aura Biosciences, Inc.
1W: -1.8%
1M: +3.0%
3M: -12.3%
YTD: +16.6%
1Y: +8.8%
3Y: -27.0%
$6.29
+0.11 (+1.78%)
After Hours: $6.30 (+0.01, +0.24%)
Weekly Expected Move ±5.9%
$6
$6
$6
$7
$7
Credit Risk of going bust: lower than 72% of companies Debt: 2.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.7%), Aura Biosciences, Inc. would be worth roughly what it owes.
Total debt $16.6M against a stock market value of $640.9M.
Distance to default 7.88 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $8.3M (short-term plus half of long-term), stock volatility 54.7%; Altman Z'' 8.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.7%), Aura Biosciences, Inc. would be worth roughly what it owes.
Total debt $16.6M against a stock market value of $640.9M.
Distance to default 7.88 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $8.3M (short-term plus half of long-term), stock volatility 54.7%; Altman Z'' 8.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$640.9M
52W Range4.73-9.54
Volume844,334
Avg Volume782,165
Beta0.41
Dividend—
Analyst Ratings
Company Info
CEONatalie C. Holles
Employees113
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-29
Websiteaurabiosciences.com
85 Bolton Street
Boston, MA 02135
US
Boston, MA 02135
US
617 500 8864
About Aura Biosciences, Inc.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Latest News
Bank of New York Mellon Corp Makes New $842,000 Investment in Aura Biosciences, Inc. $AURA
Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.
BlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURA
ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA
Research Analysts Set Expectations for AURA Q1 Earnings
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kratz Erica | A-Award | 100,885 | — | 2026-09-01 |
| Kratz Erica | A-Award | 199,115 | $7.43 | 2026-09-01 |
| Hopkins Janet Jill | A-Award | 58,850 | — | 2026-09-01 |
| Hopkins Janet Jill | A-Award | 116,150 | $7.43 | 2026-09-01 |
| Elazzouzi Amy | A-Award | 23,540 | — | 2026-09-01 |